Weekly Recap: Revenue +48% from obesity drugs and Foundayo FDA approval
Eli Lilly and Company (NYSE:LLY) rode blockbuster obesity drugs Mounjaro and Zepbound to 48% Q2 revenue growth and FDA wins for oral Foundayo while expanding manufacturing, striking big deals, facing a $90M patent jury award, and seeing bullish forecasts as payer moves and trial data reshape demand…